Search

Issue
Title
Authors
Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence
Editorial B.
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Shlivko I.L., Garanina O.E., Artamonova E.V., Ganshina I.P., Zhukova L.G., Koroleva I.A., Michenko A.V., Semiglazova T.Y., Filonenko D.A.
The possibilities of therapy of patients with metastatic colorectal cancer with BRAF V600E mutation. Clinical cases
Polyanskaya E.M., Fedyanin M.I.
Nasledstvennyy rak zheludka: molekulyarno-geneticheskie i klinicheskie aspekty
Nikulin M.P., Lyubchenko L.N., Sel'chuk V.Y., Stilidi I.S.
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Mazurina N.V., Artamonova E.V., Beloyartseva M.F., Volkova E.I., Ganshina I.P., Troshina E.A., Tjulandin S.A., Chubenko V.A.
Molekulyarno-biologicheskie faktory prognoza pri B-kletochnom khronicheskom limfoleykoze
Nikitin E.A., Malakho S.G., Biderman B.V., Poltaraus A.B., Sudarikov A.B.
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
Poddubnaya I.V., Gligorov J., Zhukova L.G., Kovalenko E.I., Frolova M.A.
New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
Laktionov K.K., Reutova E.V., Nelyubina L.A., Pitkevich M.Y., Okruzhnova M.A., Ardzinba M.S., Yudin D.I., Demidova I.A., Zaretsky A.R.
The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
Ryazhenov V.V.
Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene
Ryazhenov V.V., Gorokhova S.G.
Supportive therapy for ovarian cancer
Pokataev I.A., Tyulyandin S.A.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib
Smolin A.V., Gorbacheva A.V.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
Press-release. «Merck Serono» announces new retrospective analysis shows significant clinical benefit in overall survival for metastatic colorectal cancer patients with RAS wild-type tumors receiving Erbitux® plus FOLFIRI
1 - 15 of 15 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies